证券代码：300253 证券简称：卫宁健康 公告编号：2025-056 卫宁健康科技集团股份有限公司 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、 获取补助的基本情况 卫宁健康科技集团股份有限公司（以下简称"公司"、"卫宁健 康"）近日收到政府补助资金 1,100 万元，单笔金额约占公司 2024 年度经审计归属于上市公司股东净利润的 12.52%。具体情况如下： | 收款单位 | 补助形式 （现金）/金 | 占公司最近 一期经审计 | 是否与公司 | 是否已经实 | 是否具有可 | | --- | --- | --- | --- | --- | --- | | | | | 日常经营活 | 际收到相关 | | | | | 净利润的比 | | | 持续性 | | | 额（万元） | | 动相关 | 款项 | | | | | 例 | | | | | 卫宁健康 | 1,100 | 12.52% | 是 | 是 | 否 | 二、 补助的类型及其对上市公司的影响 1、补助的类型 公司根据《企业会计准则第 16 号—政府补助》的规定进行会计 ...

Index Performance - The CSI A500 Index increased by 1.32% this week, closing at 4662.51 points on July 4 [4] - The average daily trading volume for the week was 18341.42 billion yuan, with a week-on-week decrease of 9.22% [4] Top Performing Stocks - The top ten stocks with the highest gains this week included: 1. Tian Shou Pharmaceutical (600521.SH) with a gain of 23.34% 2. Daqian Energy (688303.SH) with a gain of 22.18% 3. Junshi Biosciences (688180.SH) with a gain of 18.93% 4. Lepu Medical (300003.SZ) with a gain of 17.99% 5. Giant Network (002558.SZ) with a gain of 17.42% 6. Tongwei Co., Ltd. (600438.SH) with a gain of 17.32% 7. Hualing Steel (000932.SZ) with a gain of 15.37% 8. Pengding Holdings (002938.SZ) with a gain of 14.57% 9. Shenzhou Taiyue (300002.SZ) with a gain of 13.70% 10. Dongshan Precision (002384.SZ) with a gain of 13.36% [3] Underperforming Stocks - The ten stocks with the largest declines this week included: 1. Hengxuan Technology (688608.SH) with a loss of 33.40% 2. Huazhi Shihua (688120.SH) with a loss of 32.34% 3. Northern Huachuang (002371.SZ) with a loss of 22.87% 4. Weining Health (300253.SZ) with a loss of 8.77% 5. China Eastern Airlines (600115.SH) with a loss of 7.07% 6. Xingyuan Material (300568.SZ) with a loss of 6.99% 7. Cambricon Technologies (688256.SH) with a loss of 6.50% 8. Beiyi Innovation (603986.SH) with a loss of 5.93% 9. Jixiang Airlines (603885.SH) with a loss of 5.84% 10. New Zhou Bang (300037.SZ) with a loss of 5.49% [3] Fund Performance - This week, 38 CSI A500 funds collectively rose, with Pu Yin An Sheng leading at a 1.72% increase [5] - The top three funds by size were Huatai-PB (200.88 billion yuan), Guotai (181.5 billion yuan), and GF Fund (174.22 billion yuan) [5] Market Trends - A new trend has emerged in the Hong Kong stock market where A-share listed technology companies are increasingly pursuing secondary listings in Hong Kong [7] - The secondary listings provide diversified financing channels and enhance international market recognition for the companies [7] - The median discount rate for five companies planning secondary listings in Hong Kong is approximately -17% [7] - The core factors driving asset performance are expected to shift from external to internal influences in the second half of the year [7]

内容概要：数字化医院是利用先进的计算机网络系统，将患者的诊疗信息、卫生经济信息与医院管理信 息等进行有效融合，经过收集、储存、传输整理后纳入医院的数据库中，为患者和医院管理者服务的信 息管理体系。信息化的发展，时代的进步，科技的发展，数字化技术的突飞猛进，改变了传统行业的工 作模式与工作方法。医院只有实现现代化、信息化才能适应社会的变革，跟上时代的发展。医院是科技 成果应用最早和最多的领域之一，为医疗的发展进步提供了不竭的原动力，信息技术对医院的渗透是历 史的必然，并蕴藏着巨大的发展潜力。近年来，我国数字化医院市场规模快速增长，2024年我国数字化 医院市场规模快速增长到487.7亿元，其中，硬件规模292.6亿元，软件规模96.7亿元，服务规模98.4亿 元；预计2025年我国数字化医院市场规模将达到525亿元，其中，硬件规模309.2亿元，软件规模106.6亿 元，服务规模109.2亿元。 上市企业：和仁科技[300550]、久远银海[002777]、思创医惠[300078]、创业慧康[300451]、东软集团 [600718]、万达信息[300168]、卫宁健康[300253] 相关企业：东华医为科技有 ...

金融界7月2日消息，上证指数高开震荡，中证互联网医疗主题指数 (CS互医疗，930720)下跌1.12%，报 2641.28点，成交额78.82亿元。 数据统计显示，中证互联网医疗主题指数近一个月上涨2.71%，近三个月上涨0.71%，年至今上涨 12.96%。 据了解，中证互联网医疗主题指数选取为医疗信息化、智能化提供硬件、软件或服务的代表性公司作为 样本，以反映互联网医疗主题相关公司的整体表现。该指数以2012年06月29日为基日，以1000.0点为基 点。 从指数持仓来看，中证互联网医疗主题指数十大权重分别为：乐普医疗（6.03%）、卫宁健康 （5.1%）、嘉和美康（5.09%）、久远银海（5.07%）、东华软件（5.07%）、创业慧康（5.05%）、思 创医惠（5.03%）、药易购（5.03%）、海尔生物（5.01%）、爱尔眼科（4.99%）。 从中证互联网医疗主题指数持仓的市场板块来看，深圳证券交易所占比56.07%、上海证券交易所占比 43.93%。 从中证互联网医疗主题指数持仓样本的行业来看，医药卫生占比64.79%、信息技术占比30.18%、通信 服务占比5.03%。 资料显示，指数样本每季度 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2025-055 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 关于 2025 年第二季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300253 证券简称：卫宁健康 债券代码：123104 债券简称：卫宁转债 2、票面金额：100 元/张，转股价格：17.31 元/股 3、2025 年第二季度，共有 0 张"卫宁转债"完成转股,转换成 公司股票 0 股。 5、转股期限：2021 年 9 月 22 日至 2027 年 3 月 15 日 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易 所可转换公司债券业务实施细则》的有关规定，卫宁健康科技集团股 份有限公司（以下简称"公司"）现将 2025 年第二季度可转换公司 债券（以下简称"可转债"）转股及公司股份变动情况公告如下： 一、可转债基本情况 1、可转债发行上市情况 经中国证券监督管理委员会"证监许可〔2021〕311 号"文同意 注册的批复，公司于 2021 年 ...

| 分析师：俞家宁 | S1050523070002 | | --- | --- | | yujn@cfsc.com.cn | | | 分析师：胡博新 | S1050522120002 | | hubx@cfsc.com.cn | | | 分析师：任春阳 | S1050521110006 | | rency@cfsc.com.cn | | | 基本数据 | 2 0 2 5-0 6-2 7 | | --- | --- | | 当前股价（元） | 10.83 | | 总市值（亿元） | 240 | | 总股本（百万股） | 2213 | | 流通股本（百万股） | 1913 | | 52 周价格范围（元） | 5.15-13.24 | | 日均成交额（百万元） | 679.41 | 2025 年 06 月 30 日 医疗智能化进程持续推进，AI 新品有望带动业 绩增长 买入(首次) 投资要点 ▌短期业绩承压，新一代产品有望推动业绩增长 2024 年，公司实现营业收入 27.82 亿元，同比减少 12.05%； 利润端，公司实现归母净利润 0.88 亿元，同比减少 75.45%， 2025 年一季度，公司实现收入 ...

医疗信息化概念股震荡走强 卫宁健康涨超10% 智通财经6月27日电，医疗信息化概念股盘中走强，卫宁健康涨超10%，迪安诊断、创业慧康涨超5%， 思创医惠、国新健康、久远银海、万达信息、塞力医疗等跟涨。 ...

Group 1 - The smart medical sector is experiencing a significant upward trend, with notable stock price increases for several companies [1] - Jincheng Pharmaceutical (300233) has seen its stock rise by over 10% [1] - Heertai (002402) and Weining Health (300253) have both increased by over 9% [1] - Yaoshi Technology (300725) has experienced a stock price increase of over 5% [1] - Other companies such as Yuandong Biology and Chengdu Xian Dao are also showing upward movement [1]

后不会对公司股本造成影响。 卫宁健康科技集团股份有限公司关于 2022 年股权激励计划部分期权注销完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）第六届董 事会第十四次会议审议通过了《关于注销部分股票期权的议案》《关 于 2022 年股权激励计划首次授予期权第三个行权期行权条件未成就 的议案》《关于 2022 年股权激励计划预留授予期权第二个行权期行权 条件未成就的议案》，同意注销 2022 年股权激励计划首次授予期权 25,284,320 份、预留授予期权 6,308,806 份，其中：23 名首次授予 激励对象、8 名预留授予激励对象因个人原因离职，不再具备激励对 象资格，同意注销已授予尚未行权的首次授予期权 1,952,680 份、预 留授予期权 705,175 份；公司 2024 年经营业绩未达到公司层面的业 绩考核指标，首次授予期权第三个行权期、预留授予期权第二个行权 期行权条件未成就，同意注销首次授予期权第三个行权期已获授期权 23,331,640 份、预留授予期权第二个行权期已获授期权 ...

Core Viewpoint - The credit rating report for Weining Health Technology Group indicates a stable outlook despite recent performance declines, driven by challenges in innovative business segments and competitive pressures in the healthcare information technology industry [3][5][6]. Company Overview - Weining Health is recognized as a leading enterprise in the domestic healthcare information industry, maintaining a market share of 13.4% in the core hospital diagnostic system sector as of 2023 [17]. - The company continues to implement its "1+X" strategy, focusing on the WiNEX series products and digital health applications [15][17]. Financial Performance - The company's revenue for 2024 was reported at 3.45 billion yuan, a decrease of 12.05% year-on-year, with a net profit of -0.03 billion yuan [4][16]. - The financial structure remains robust, with total debt at 11.62 billion yuan and equity at 60.30 billion yuan as of March 2025 [4][5]. - The company’s cash flow from operating activities was negative at -0.26 billion yuan, indicating liquidity challenges [4]. Business Segments - The healthcare information technology segment remains the primary revenue source, contributing 2.92 billion yuan in 2024, but faced a decline of 14.17% [16][19]. - The internet healthcare segment showed slight revenue growth, but overall performance is still impacted by losses in innovative business areas [24][25]. Market Environment - The healthcare information technology industry is experiencing growth, with a projected market size of 230.3 billion yuan in 2024, driven by policy support and AI technology integration [10][11]. - The industry faces high competition and rapid technological changes, necessitating continuous innovation and adaptation from companies [6][10]. Innovation and R&D - The company has been focusing on enhancing its R&D capabilities, with a significant investment in AI and digital health solutions, although R&D personnel and investment amounts have decreased recently [23][24]. - The introduction of new products, such as the WiNGPT2.8 and WiNEX Copilot 2.1, aims to strengthen the company's competitive position in the market [23]. Customer Base and Sales - The primary customers are public hospitals and health management departments, with a low customer concentration risk as the top five clients account for only 5.61% of total sales [19][21]. - The sales model primarily involves direct sales through competitive bidding, with payment structures that include prepayments and milestone payments [18]. Future Outlook - The company maintains a stable credit rating outlook, supported by its competitive advantages in core hospital systems and ongoing technological advancements [5][6]. - However, the future profitability of innovative business segments remains uncertain, with ongoing losses and the need for strategic adjustments [24][25].